1. Clinical Need
Coronary artery disease is the leading cause of death in the United States, responsible for approximately 375,000 deaths annually. Percutaneous coronary intervention with stent implantation is the standard revascularization procedure, with roughly 600,000 PCI procedures performed in the US each year. Drug-eluting stents reduced restenosis rates compared to bare-metal predecessors, but the problem persists: a 2024 systematic review and meta-analysis of 17 studies encompassing 126 to 5,355 patients per study found a pooled in-stent restenosis incidence of approximately 13% with contemporary drug-eluting stents (Liu et al., Reviews in Cardiovascular Medicine, 2024; DOI: 10.31083/j.rcm2512458). In clinical practice, ISR rates range from 5% to 15% depending on lesion complexity, patient comorbidities, and stent generation.
The clinical burden is concentrated in surveillance. Current ISR detection requires invasive coronary angiography — a catheterization procedure costing $1,708 per case in hospital outpatient settings and $3,312 inpatient (CPT 93454, 2026 Medicare rates). The American College of Cardiology recommends follow-up angiography for symptomatic patients and stress testing for asymptomatic surveillance, but neither approach detects early-stage restenosis before hemodynamic compromise. By the time symptoms appear or stress tests become abnormal, the vessel has typically narrowed by 50% or more, requiring repeat intervention.
This reactive surveillance model costs the US healthcare system an estimated $1.8–2.4 billion annually in follow-up catheterizations and repeat PCIs for ISR. More critically, it misses the therapeutic window where pharmacological or lifestyle interventions could slow neointimal hyperplasia before mechanical re-intervention becomes necessary. The unmet clinical need is a continuous, non-invasive hemodynamic monitoring capability embedded within the stent itself — converting the implant from a passive structural scaffold into an active diagnostic platform that transmits restenosis data wirelessly, enabling clinician intervention at the earliest detectable stage.
2. State of the Art
Four independent research paradigms have converged on wireless smart stent sensing, each validated in animal models but none yet available as commercial products.
Magnetoelastic self-powered sensing
Jun Chen’s laboratory at UCLA published the first self-powered magnetoelastic coronary stent in Nature Cardiovascular Research (2026, Vol. 5, pp. 155–167; DOI: 10.1038/s44161-025-00773-4), featured as the journal’s cover article. The magnetoelastic effect converts vascular wall motion directly into electrical signals without batteries or external power. The stent was deployed in swine carotid arteries using standard clinical catheters and detected induced stenosis through AI-assisted signal interpretation. Biosafety was validated through immune profiling, human cytokine analysis, and single-cell RNA sequencing. Funded by NIH R01 HL175135.
Radar backscattering long-range wireless
Woon-Hong Yeo’s laboratory at Georgia Tech achieved the longest wireless communication range in the field — 50 cm via 2 GHz radar backscattering — using a conformal capacitive pressure sensor on a low-resistance inductive stent (Bateman et al., ACS Applied Materials & Interfaces, 2025, Vol. 17(30), pp. 42781–42790; DOI: 10.1021/acsami.5c08212). The system detects 50% stent-edge restenosis through localized pressure signal changes. Earlier work from the same group demonstrated fully implantable wireless batteryless vascular electronics in rabbit iliac arteries with 5.5 cm range in air and 3.5 cm through blood (Herbert et al., Science Advances, 2022; DOI: 10.1126/sciadv.abm1175).
Impedance-based thrombus and restenosis detection
Hoare et al. at the University of Glasgow demonstrated real-time wireless thrombus detection in swine models (Communications Medicine, 2024, Vol. 4, Article 15; DOI: 10.1038/s43856-024-00436-8). Blood versus clot discrimination achieved p<0.001 statistical significance, with thrombus detected within 4–5 minutes of occlusion onset (p=0.01 at 4 min). The impedance approach distinguishes blood, thrombus, smooth muscle cells, and calcified versus lipid-rich plaque — providing compositional data beyond pressure sensing alone.
Resonant frequency shift pressure sensing
Chen and Takahata at UBC demonstrated the earliest mechanically robust smart stent prototype, surviving crimping forces exceeding 100 N and 16 atm balloon expansion while maintaining wireless pressure sensitivity of 93 ppm/mmHg (Advanced Science, 2018; DOI: 10.1002/advs.201700560). This established that wireless sensing electronics can withstand the mechanical stresses of standard interventional cardiology deployment procedures.
The field is converging on clinical translation. What remains absent from all published systems: (a) AI-driven adaptive baseline learning that personalizes detection thresholds to individual patient hemodynamics, (b) manufacturing processes capable of producing sensor-integrated stents at volumes compatible with the existing coronary stent supply chain, and (c) regulatory clearance under a defined FDA pathway.
3. Foundational Research
Chen J et al. (2026). “Self-powered in-stent restenosis diagnosis via magnetoelastic stents.” Nature Cardiovascular Research, 5, 155–167. DOI: 10.1038/s44161-025-00773-4.
First self-powered smart stent validated in large animal models. Deployed in swine carotid arteries via standard clinical catheters. The magnetoelastic transduction mechanism eliminates batteries and external power sources — vascular wall pulsatile motion generates the sensing signal directly. AI-assisted signal interpretation detected induced stenosis. Biosafety demonstrated via immune profiling and single-cell RNA sequencing. Funded by NIH R01 HL175135. Establishes that batteryless chronic hemodynamic monitoring is feasible through a stent deployed with existing catheterization infrastructure.
Bateman A, He Y, Cherono C, Lee J, Ghalichechian N, Yeo WH (2025). “Implantable Membrane Sensors and Long-Range Wireless Electronics for Continuous Monitoring of Stent Edge Restenosis.” ACS Applied Materials & Interfaces, 17(30), 42781–42790. DOI: 10.1021/acsami.5c08212. PMC12314858.
Achieved 50 cm wireless communication range via radar backscattering at 2 GHz with quality factor 8.9 — an order-of-magnitude improvement over prior inductive coupling approaches limited to 2–5 cm. The conformal capacitive pressure sensor detected 50% stent-edge restenosis through a 5 MHz frequency shift in a pulsatile-flow silicone arterial model (60 BPM, ~1.5 mL stroke volume). The 50 cm range enables readout through the chest wall using a handheld or wearable external device without requiring hospital visits.
Hoare D, Kingsmore D, Holsgrove M, Russell E, Kirimi MT et al. (2024). “Realtime monitoring of thrombus formation in vivo using a self-reporting vascular access graft.” Communications Medicine, 4, Article 15. DOI: 10.1038/s43856-024-00436-8. PMC10844314.
Swine model (n=5: 2 non-recovery, 2 recovery, 1 cadaver). Impedance spectroscopy discriminated blood from clot with p<0.001 significance. Thrombus detected at 4–5 minutes post-occlusion (p=0.01 at 4 min). Smooth muscle cells distinguished from endothelial cells at p<0.0001 (100 kHz). Calcified plaque distinguished from lipid-rich plaque at p<0.01. Validates multi-parameter tissue characterization from an implanted wireless sensor — detecting not just restenosis occurrence but its composition.
Oyunbaatar NE, Kim DS, Shanmugasundaram A, Kim SH, Jeong YJ et al. (2023). “Implantable Self-Reporting Stents for Detecting In-Stent Restenosis and Cardiac Functional Dynamics.” ACS Sensors, 8(12), 4542–4553. DOI: 10.1021/acssensors.3c01313. PMID: 38052588.
Demonstrated in vivo self-reporting stent function in rats with dual-pressure sensors monitoring both blood pressure and flow simultaneously. Achieved 2-fold improvement in sensing resolution and coupling distance over prior generation. Established that chronic implanted stent sensors maintain function and biocompatibility in living vascular tissue — a prerequisite for clinical translation.
Herbert R, Elsisy M, Rigo B, Lim HR, Kim H et al. (2022). “Fully implantable batteryless soft platforms with printed nanomaterial-based arterial stiffness sensors for wireless continuous monitoring of restenosis in real time.” Nano Today, 46, 101557. DOI: 10.1016/j.nantod.2022.101557. PMC9970263.
University of Pittsburgh. Printed nanomaterial strain sensors achieved gauge factor 10.5 — ten times greater than typical soft capacitive sensors — with 60% capacitance change at 4.8% strain and resolution down to 0.15% strain. Validated ex vivo in ovine hearts. This sensitivity level enables detection of early neointimal hyperplasia before hemodynamically significant stenosis develops.
Chen X, Assadsangabi B, Hsiang Y, Takahata K (2018). “Enabling Angioplasty-Ready ‘Smart’ Stents to Detect In-Stent Restenosis and Occlusion.” Advanced Science, 5(5), 1700560. DOI: 10.1002/advs.201700560. PMID: 29876203.
UBC. Foundational mechanical robustness demonstration: gold-coated stent survived crimping exceeding 100 N and 16 atm balloon expansion — standard interventional cardiology deployment forces. Wireless pressure sensitivity: 93 ppm/mmHg. Quality factor: 43 (10x improvement over bare stent Q ~4). Resonant frequency range: 27.96–42.5 MHz. This established that wireless sensing is compatible with the mechanical requirements of real clinical stent deployment.
4. Competitive Landscape
VesselSens GmbH (Bonn, Germany). Coordinator of the EU-funded StentGuard project (EIC Accelerator, Project ID 190107486, total budget EUR 11.3M, EU contribution EUR 2.5M, October 2022–July 2025). StentGuard’s stated objective was clinical validation of the first implantable sensor system for wireless detection of stent occlusion/restenosis. The project closed in July 2025. Current product status and clinical trial results are not publicly available.
Triton Systems, Inc. (Chelmsford, MA). Received ARPA-H SBIR Phase II award of $4.1M in September 2024 (Award 75N91024C00034) for an implantable coronary stent with dual functionality: structural vessel support plus continuous cardiovascular monitoring targeting vessel flow, arterial pressure, and troponin levels.
Calyx Systems (New York, NY). Received ARPA-H SBIR award of $4.0M in September 2024 for BioSMART, an electronically-enhanced smart stent monitoring vascular health, hemodynamic parameters, restenosis, thrombosis, and myocardial infarction biomarkers.
No commercial wireless restenosis-monitoring stent exists. Major stent incumbents — Boston Scientific, Medtronic, and Abbott — are not publicly developing wireless smart stent sensing. Their ISR-related R&D focuses on treatment (Boston Scientific received FDA approval for the AGENT Drug-Coated Balloon in March 2024 specifically for treating coronary ISR). The detection and monitoring space remains pre-commercial and driven by academic labs and SBIR-funded startups.
5. Addressable Scope
Bottom-up calculation (US coronary stent monitoring)
- Annual PCI procedures (US): ~600,000 (American Heart Association statistics, 2024)
- ISR incidence requiring detection: 5–15% = 30,000–90,000 patients annually requiring surveillance
- Current surveillance cost per patient: $1,708–$3,312 per angiography (CPT 93454, 2026 Medicare)
- Smart stent device premium: $2,500 per unit over conventional DES (~$1,500 baseline)
- Addressable PCI procedures (30% penetration at steady state): 180,000 procedures/year
- Device revenue: 180,000 × $2,500 = $450M/year US device revenue
- RPM monitoring revenue per patient: $1,248/year (CPT 99453 setup + 99454 device supply + 99457 management)
- Monitoring revenue (year 5, cumulative pool ~540,000): $674M/year US monitoring revenue
- Combined US TAM at steady state: $1.12B/year
Top-down cross-check
The smart stent market was valued at $2.32 billion in 2024 and is projected to reach $4.2–10.5 billion by 2033, representing a 13–18% CAGR (DataM Intelligence, 2024). The broader coronary stent market is $8.3–10.4 billion (Precedence Research, 2025; Mordor Intelligence, 2025) growing at 4.7–6% CAGR through 2034. The bottom-up US estimate of $1.12B is consistent with US representing approximately 25–30% of the conservative $4.2B global smart stent projection.
Reimbursement pathway
Remote physiological monitoring CPT codes 99453–99458 provide an existing billing mechanism without requiring new code creation. RPM revenue of ~$104/month per patient represents recurring economics on top of the device sale. Smart stent monitoring would also reduce or eliminate follow-up coronary angiographies (CPT 93454, $1,708/procedure), creating a cost-saving argument for payer adoption: continuous wireless monitoring at $1,248/year replaces periodic invasive surveillance at $1,708+ per catheterization episode.
6. Research Gaps and HHA Contribution
Three specific gaps separate published laboratory prototypes from a deployable clinical product. Each gap maps directly to an HHA team capability.
Gap 1: AI-driven adaptive patient-specific monitoring
All published smart stent systems use fixed thresholds or simple signal processing for stenosis detection. No system implements machine learning that adapts to individual patient hemodynamic baselines — learning the patient’s normal pressure waveform, flow velocity profile, and impedance signature post-implantation, then detecting deviations that indicate early neointimal hyperplasia. The UCLA group’s AI-assisted interpretation is the closest approach, but their published methodology uses classification rather than adaptive baseline learning.
Under FDA’s December 2024 finalized PCCP (Predetermined Change Control Plan) guidance, an adaptive algorithm requires a structured change control plan — a regulatory instrument that simultaneously creates compliance burden for competitors and intellectual property protection for the first filer. A locked algorithm follows a simpler regulatory path but sacrifices the clinical advantage of personalization.
HHA contribution: Haedar Hadi (Lead PI, MS Computer Science, Boston University, Information Systems focus) leads the adaptive algorithm architecture — time-series classification from multi-parameter sensor data, patient-specific baseline learning, PCCP-compliant model update framework, and evaluation methodology (sensitivity, specificity, positive predictive value benchmarking against angiographic ground truth).
Gap 2: Scalable manufacturing for sensor-integrated stents
Current prototypes are fabricated through serial laboratory processes: manual assembly of MEMS sensors onto stent scaffolds, electron-beam lithography, individual laser micromachining, and hand-soldered wireless components. Clinical adoption at the volumes required by the coronary stent market — 600,000+ US procedures annually — requires batch fabrication with sub-dollar sensor costs and medical device quality systems (ISO 13485, 21 CFR 820). The transition from serial research fabrication to parallel production with incoming material inspection, in-process controls, and batch record traceability is a manufacturing engineering challenge that academic laboratories are structurally unable to address.
HHA contribution: Ahmed Dhia (Director of Manufacturing) provides the manufacturing engineering capability that bridges laboratory proof-of-concept to production-ready medical devices. His expertise in design for manufacturability, production scaling, and quality systems directly addresses the single highest-risk technical barrier where most funded smart stent research stalls. Academic labs publish sensing results but cannot build manufacturing lines, establish incoming material inspection protocols, or implement batch record traceability under ISO 13485. Ahmed’s background closes exactly this gap — transitioning from serial two-photon polymerization and electron-beam lithography to batch fabrication at clinical volumes with full quality system compliance.
Gap 3: Defined regulatory and reimbursement architecture
The FDA pathway for a wireless smart stent is not a single submission but a multi-track strategy. The stent scaffold component follows the established PMA (Class III) pathway for coronary drug-eluting stents (product code NIQ). The wireless sensing module should be architecturally separated to pursue De Novo classification as a Class II device — following the precedent established by Canary Medical’s Persona IQ smart knee implant sensor (De Novo authorization, August 2021) and Epiminder’s Minder iCEM implantable wireless EEG monitor (De Novo, Breakthrough designation, 2025). Abbott’s CardioMEMS HF System (PMA 2014) — a wireless, batteryless, catheter-implanted pulmonary artery pressure sensor — is the closest functional analog and demonstrates FDA comfort with wireless intravascular sensing. The entity that navigates this multi-track regulatory architecture first defines the predicate device for all subsequent entrants.
HHA contribution: Hass Dhia (Co-PI, MS Biomedical Sciences, Wayne State University School of Medicine) leads regulatory strategy formulation, clinical trial design, and translational framing. His biomedical domain expertise — coronary vascular anatomy, hemodynamic physiology, neointimal hyperplasia pathology — grounds the regulatory narrative in clinical language that FDA reviewers and interventional cardiologists recognize. The combination of biomedical training and AI infrastructure architecture experience enables the modular regulatory strategy (PMA + De Novo + PCCP) that separates device components into distinct, optimized regulatory tracks.
Why incumbents have not closed these gaps
Boston Scientific, Medtronic, and Abbott generate revenue from the current reactive model: their drug-coated balloons and second-generation DES treat restenosis after it occurs. Continuous monitoring could reduce repeat intervention volume — a revenue cannibalization risk for companies whose business models depend on procedure volume. Additionally, their core R&D competencies are in mechanical and chemical engineering (stent design, polymer coatings, drug formulation), not wireless electronics, MEMS fabrication, or embedded machine learning. The organizational and incentive structures of $50B+ medical device companies make it structurally difficult to build the cross-disciplinary teams required for sensor-integrated stent development.
7. Comparable Funded Projects
| Source | PI / Entity | Amount | Focus |
|---|---|---|---|
| ARPA-H SBIR Phase II | Triton Systems, Chelmsford MA | $4.1M (2024) | Implantable stent with flow/pressure/troponin monitoring and wireless app data transmission. Demonstrates ARPA-H’s appetite for smart stent investment at the $4M+ level, validating the technology category as translational rather than basic research. |
| ARPA-H SBIR | Calyx Systems, New York NY | $4.0M (2024) | BioSMART electronically-enhanced stent for hemodynamic monitoring, restenosis/thrombosis detection. Combined with Triton, signals $8.1M in ARPA-H smart stent investment in a single fiscal year. |
| NIH NHLBI R01 (HL175135) | Jun Chen, UCLA | ~$1.5M est. (2024–ongoing) | Self-powered magnetoelastic stent with AI-assisted stenosis detection validated in swine. The Nature Cardiovascular Research cover article demonstrates the highest academic validation level for smart stent technology. |
| NIH NIBIB R03 (EB028928) | Young Jae Chun, Pittsburgh | ~$150K (2020–2022) | Electronic stent with stretchable nanostructured sensors for batteryless wireless monitoring. Smaller award demonstrating NIH NIBIB engagement with smart stent sensing technology. |
| NSF (3-year grant) | Woon-Hong Yeo, Georgia Tech | $400K (2022–2025) | Fully implantable wireless vascular electronics with printed soft sensors. NSF engagement indicates cross-agency interest spanning ARPA-H, NIH, and NSF. |
| EU EIC Accelerator | VesselSens GmbH (StentGuard) | EUR 11.3M total / EUR 2.5M EU (2022–2025) | Clinical validation of first implantable sensor for wireless restenosis detection. The largest single investment in smart stent commercialization globally, representing the most advanced (and now concluded) effort to bring wireless restenosis monitoring to clinical use. |
Federal agencies have committed over $12M to smart stent development in the past two years, with ARPA-H’s $8.1M in combined SBIR awards signaling that the technology category has crossed from basic research into translational investment. The EU’s EUR 11.3M StentGuard project represents the most advanced commercialization effort internationally. This funding pattern validates both the technical feasibility and the funder appetite for wireless restenosis monitoring.
8. Opportunity Assessment
TRL evidence chain
TRL 4–5 — validated in relevant environment. Chen et al. (2026) deployed a functioning magnetoelastic stent in swine carotid arteries via standard clinical catheters and detected induced stenosis with AI assistance (TRL 5). Herbert et al. (2022) implanted wireless batteryless sensors in rabbit iliac arteries with real-time hemodynamic readout (TRL 5). Hoare et al. (2024) demonstrated thrombus detection in swine with p<0.001 discrimination (TRL 5). Bateman et al. (2025) achieved 50 cm wireless range in a realistic pulsatile-flow model (TRL 4). Not yet tested in chronic large-animal coronary models specifically — multi-month coronary implantation studies remain outstanding.
Top 3 technical risks
Chronic biocompatibility and sensor stability
The longest published in vivo smart stent study spans weeks, not the 5+ years required for coronary implants. Sensor materials (gold, SU-8, soft dielectrics) must maintain electrical properties under continuous exposure to blood, endothelial overgrowth, and inflammatory responses.
Mitigation: Leverage biocompatibility data from CardioMEMS (>10 years implant duration, PMA-supporting data) and established hemocompatible coatings (heparin, phosphorylcholine). Accelerated aging per ASTM F2003 and ISO 10993 biocompatibility testing.
HighSignal reliability through neointimal tissue overgrowth
As endothelial tissue covers the stent struts (a desired healing response), sensor sensitivity may degrade. Neointimal tissue thickness varies from 100 μm to 2 mm.
Mitigation: The impedance spectroscopy approach (Hoare et al.) characterizes tissue composition directly — neointimal overgrowth changes the impedance signature in a detectable way. Signal calibration algorithms can account for tissue growth as a measured variable, not a confound.
ModerateElectromagnetic interference in clinical environments
MRI compatibility and interference from other wireless medical devices must be characterized for any implantable wireless sensor.
Mitigation: The passive resonant approach (no active electronics, no batteries) inherently simplifies EMC. The UBC group demonstrated MRI compatibility of resonant smart stent designs. RF interference testing per IEC 60601-1-2 is a standard regulatory requirement with established protocols.
ModerateRegulatory pathway
Modular regulatory strategy: (1) Stent scaffold — PMA (Class III), product code NIQ, following established drug-eluting stent pathway with IDE clinical trials; (2) Wireless sensing module — De Novo (Class II) as a separable component, following Persona IQ (2021) and Epiminder Minder (2025) precedent for wireless implant sensors; (3) AI algorithm — if locked after training, standard device software pathway; if adaptive on-device, PCCP submission required per FDA’s December 2024 finalized guidance. CardioMEMS HF System (PMA 2014) serves as the closest functional predicate for wireless intravascular hemodynamic monitoring. Estimated regulatory timeline: 12–18 months for pre-submission meetings and classification strategy, 2–3 years for IDE-enabling studies, 1–2 years for De Novo review. Total: 4–6 years to market authorization.
9. Team Capabilities
Successful pursuit of this research direction requires three intersecting capabilities. HHA’s team provides coverage across all three:
Hass Dhia
MS Biomedical Sciences (Wayne State University School of Medicine). AI infrastructure architect with production systems at scale. Provides the biomedical domain expertise required for coronary vascular anatomy modeling, hemodynamic physiology analysis, neointimal hyperplasia pathology characterization, and clinical trial design. Leads experimental methodology, regulatory strategy formulation (modular PMA + De Novo + PCCP architecture), and translational framing for FDA pre-submission engagement.
Haedar Hadi
MS Computer Science (Boston University, Information Systems focus). Specializes in ML model development, time-series classification, and evaluation methodology. Provides the machine learning expertise required for adaptive patient-specific hemodynamic monitoring — baseline learning algorithms that personalize detection thresholds from multi-parameter sensor data (pressure, impedance, flow), PCCP-compliant adaptive algorithm architecture with structured change control plans, and evaluation framework design (sensitivity, specificity, PPV benchmarking against angiographic ground truth). Leads technical infrastructure and AI algorithm development.
Ahmed Dhia
Senior manufacturing engineer with deep expertise in design for manufacturability (DFM), production scaling, and quality systems. Provides the manufacturing engineering capability that bridges laboratory proof-of-concept to production-ready medical devices — specifically, the transition from serial MEMS assembly and electron-beam lithography to batch fabrication at clinical volumes with ISO 13485 compliance, incoming material inspection, in-process controls, and batch record traceability.
This is the precise capability gap where most funded smart stent research stalls. Academic labs publish sensing results and animal model validations, but they cannot build manufacturing lines, establish quality systems, or produce sensor-integrated stents at the volumes required by the coronary stent supply chain (600,000+ US procedures/year). Ahmed’s background in production scaling and quality systems directly addresses Gap 2 — the single highest-risk technical barrier identified in this assessment and the barrier that separates published prototypes from deployable clinical products.
10. Recommended Next Steps
Target funding programs
| Program | Mechanism | Range | Fit |
|---|---|---|---|
| ARPA-H Open BAA | Performer agreement | $1M–$10M | High-risk, high-reward health technology; AI-driven implantable diagnostics fits “proactive health” thrust. ARPA-H has already invested $8.1M in smart stent SBIR awards in FY2024, signaling active program interest. |
| NIH NHLBI | R01 / R21 | $250K–$500K/yr | Cardiovascular device innovation; adaptive monitoring algorithms for coronary hemodynamics. Direct alignment with NHLBI’s existing R01 funding of Chen lab’s magnetoelastic stent work. |
| NIH NIBIB | R01 / R21 | $250K–$500K/yr | Biomedical imaging and bioengineering; wireless implantable sensor systems. NIBIB has funded smart stent R03 awards, indicating receptivity to the technology class. |
| NSF ECCS / CBET | Standard grant | $300K–$500K/yr | Electronic, communication, and cyber systems; MEMS fabrication scaling and wireless biotelemetry. NSF has funded Yeo lab’s wireless vascular electronics work. |
| Schmidt Sciences | Open RFP | $1M–$5M+ | Embodied AI for real-world clinical applications; convergence of AI algorithms + physical implantable systems + patient outcome data. |
Estimated total funding range: $1.5M–$8M over 24–36 months for Phase 1 (adaptive algorithm validation + manufacturing feasibility + FDA pre-submission).
24-month milestone timeline
- M1–3 Systematic literature review and prior art analysis. Acquisition of hemodynamic time-series datasets from published smart stent studies for algorithm training. Initial adaptive baseline learning architecture design. FDA regulatory landscape mapping and pre-submission meeting preparation.
- M4–8 Adaptive monitoring algorithm v1 trained on simulated and published hemodynamic data. Patient-specific baseline learning validated against retrospective angiographic outcomes. Manufacturing process survey: DFM analysis for batch MEMS sensor integration onto commercial stent scaffolds. Pre-submission meeting with CDRH to confirm modular regulatory strategy (PMA + De Novo + PCCP).
- M9–14 Algorithm validation using benchtop pulsatile-flow models with induced stenosis progression. Batch fabrication proof-of-concept: target 100+ sensor-integrated stents per batch with <10% rejection rate. PCCP draft for adaptive algorithm change control. Quality system gap analysis (ISO 13485, 21 CFR 820).
- M15–20 In vitro validation of complete system (stent + sensor + wireless readout + adaptive algorithm) in patient-specific coronary artery phantoms. Manufacturing scale-up to 1,000+ units/batch. De Novo classification strategy finalized with FDA feedback. Biocompatibility testing initiation per ISO 10993.
- M21–24 Publication of adaptive algorithm performance results (sensitivity, specificity, PPV vs. angiographic ground truth). IDE-enabling study protocol design for chronic large-animal coronary model. Phase 2 funding application for animal validation + manufacturing qualification + De Novo submission.